WO2007098283A3 - Use of antagonists of maif receptor complex molecules and neurotrophic factors for treatment of neurological diseases and disorders - Google Patents

Use of antagonists of maif receptor complex molecules and neurotrophic factors for treatment of neurological diseases and disorders Download PDF

Info

Publication number
WO2007098283A3
WO2007098283A3 PCT/US2007/005078 US2007005078W WO2007098283A3 WO 2007098283 A3 WO2007098283 A3 WO 2007098283A3 US 2007005078 W US2007005078 W US 2007005078W WO 2007098283 A3 WO2007098283 A3 WO 2007098283A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
maif
receptor complex
antagonists
treatment
Prior art date
Application number
PCT/US2007/005078
Other languages
French (fr)
Other versions
WO2007098283A2 (en
Inventor
Daniel H S Lee
Anthony Rossomando
Paul H Weinreb
Original Assignee
Biogen Idec Inc
Daniel H S Lee
Anthony Rossomando
Paul H Weinreb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Daniel H S Lee, Anthony Rossomando, Paul H Weinreb filed Critical Biogen Idec Inc
Publication of WO2007098283A2 publication Critical patent/WO2007098283A2/en
Publication of WO2007098283A3 publication Critical patent/WO2007098283A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, and axonal regeneration including CNS disorders, stroke, or spinal injury, by administration of a MAIF receptor complex molecule antagonist and a neurotrophic factor.
PCT/US2007/005078 2006-02-27 2007-02-27 Use of antagonists of maif receptor complex molecules and neurotrophic factors for treatment of neurological diseases and disorders WO2007098283A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77665706P 2006-02-27 2006-02-27
US60/776,657 2006-02-27
US83145906P 2006-07-18 2006-07-18
US60/831,459 2006-07-18

Publications (2)

Publication Number Publication Date
WO2007098283A2 WO2007098283A2 (en) 2007-08-30
WO2007098283A3 true WO2007098283A3 (en) 2008-10-09

Family

ID=38438026

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/005078 WO2007098283A2 (en) 2006-02-27 2007-02-27 Use of antagonists of maif receptor complex molecules and neurotrophic factors for treatment of neurological diseases and disorders

Country Status (1)

Country Link
WO (1) WO2007098283A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2248899E (en) 2003-03-19 2015-09-23 Biogen Ma Inc Nogo receptor binding protein
ES2395094T3 (en) 2004-06-24 2013-02-08 Biogen Idec Ma Inc. Treatment of conditions that involve demyelination
EP2238986A3 (en) 2005-07-08 2010-11-03 Biogen Idec MA Inc. Sp35 antibodies and uses thereof
JP2009544703A (en) 2006-07-24 2009-12-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド Method for promoting myelination, neuronal survival and oligodendrocyte differentiation by administration of an Sp35 or TrkA antagonist
WO2008027526A1 (en) * 2006-08-31 2008-03-06 Biogen Idec Ma Inc. Methods relating to peripheral administration of nogo receptor polypeptides
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CA2701189C (en) * 2007-10-11 2017-05-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
WO2010005570A2 (en) 2008-07-09 2010-01-14 Biogen Idec Ma Inc. Compositions comprising antibodies to lingo or fragments thereof
CA2735193A1 (en) * 2008-08-26 2010-03-11 Macrogenics, Inc. T-cell receptor antibodies and methods of use thereof
CA2774260C (en) 2009-09-16 2018-10-09 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
EA030716B1 (en) 2012-05-14 2018-09-28 Байоджен Ма Инк. Lingo-2 antagonists for treatment of conditions involving motor neurons
CN102716470B (en) * 2012-06-28 2015-02-04 中国人民解放军第三军医大学第三附属医院 Medicine composite for treating peripheral nerve injury
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders
EP3302465A1 (en) 2015-06-05 2018-04-11 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215770A1 (en) * 2004-03-26 2005-09-29 Human Genome Sciences, Inc. Antibodies against Nogo receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215770A1 (en) * 2004-03-26 2005-09-29 Human Genome Sciences, Inc. Antibodies against Nogo receptor

Also Published As

Publication number Publication date
WO2007098283A2 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
WO2007098283A3 (en) Use of antagonists of maif receptor complex molecules and neurotrophic factors for treatment of neurological diseases and disorders
WO2006017673A3 (en) Taj in neuronal function
CN104059013B8 (en) 1-aryl-3-azabicyclo [3.1.0] hexane: its preparation method and for treating the purposes of neuropsychiatric disorders
EP2698166A3 (en) Complement inhibition for improved nerve regeneration
WO2008008517A3 (en) Bridged diazepan orexin receptor antagonists
ATE481407T1 (en) NEW DIAZABICYCLIC ARYL DERIVATIVES AND MEDICAL USE THEREOF
CL2010001173A1 (en) Compounds derived from substituted 1,4-diazepam, ox1 and ox2 antagonists; Useful to prepare a medicine for the treatment or prevention of a sleep disorder, to enhance the quality of sleep, and to treat or control obesity. (divisional sol. 3441-07)
CY1112374T1 (en) SELECTIONS OF THE NICOTINIC SUBSIDIARY RECEPTOR OF ACETYLCHOLINE AMIDIA
WO2007126934A3 (en) Amidoethylthioether orexin receptor antagonists
IL176260A0 (en) Diazabicyclic aryl derivatives as cholinergic receptor modulators
ATE467634T1 (en) NOVEL 1,4-DIAZA-BICYCLOÄ3.2.2ÜNONYL-OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL USE
WO2006067428A3 (en) 1, 2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands
ATE493415T1 (en) NEW DIAZABICYCLIC ARYL DERIVATIVES AND MEDICAL USE THEREOF
WO2007061763A3 (en) Indole orexin receptor antagonists
IL159350A0 (en) Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury
WO2006058868A8 (en) Substituted pteridines for treating inflammatory diseases
WO2006113140A3 (en) Novel compounds useful for bradykinin b1 receptor antagonism
NO20082923L (en) Use of a CB1 antagonist to treat side effects and negative symptoms of schizophrenia
WO2006048248A3 (en) Novel anthranilamide pyridinureas as vegf receptor kinase imhibitors
WO2008008359A3 (en) Benzofuro-and benzothienopyryimidine modulators of the histamine h4 receptor
WO2007047447A3 (en) Diuretic-like compound analogs useful for regulation of central nervous system disorders
WO2007058805A3 (en) Compositions and methods for treating cns disorders
WO2005097778A8 (en) Tetrahydrobenzazepines as histamine h3 receptor ligands
WO2006135694A3 (en) Uii-modulating compounds and their use
WO2004110359A3 (en) Fusion proteins for the treatment of cns

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07751811

Country of ref document: EP

Kind code of ref document: A2